NCT04204850 - Cabozantinib to Treat Recurrent Liver Cancer Post Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

August 7, 2025

Study Completion Date

December 7, 2025

Conditions

Hepatocellular CarcinomaRecurrent CancerLiver Transplant

Interventions

DRUG

Cabozantinib

Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.

Trial Locations (1)

RECRUITING

Princess Margaret Cancer Centre, Toronto